We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
News

PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates

PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
News

PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The new addition was unveiled at the 1st annual Society for Laboratory Automation and Screening Conference, in San Diego.

The expansion of the Epigenetic Biochemical Toolbox increases the portfolio to over 35 validated enzymatic assays for the detection of post-translational modifications of histone H3 and p53. The assays cover all the major writer and eraser enzyme families including HDACs, Sirtuins, HATs, HMTs and demethylases. This newly expanded portfolio helps researchers explore epigenetics-based therapeutic candidates for cancer and neurodegenerative disorders.

"This new addition to our epigenetics portfolio is part of a series of innovations to create a full breadth of offerings to advance personalized medicine research," said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. "We are taking active steps to continue to transform PerkinElmer into one of the leading providers of technologies, services and products to enable researchers in this expanding market."

The new AlphaLISA(R) Epigenetic Cellular Detection Kits enable rapid and direct detection of endogenous modification of epigenetic marks on Histone H3, all in a one-well, no-wash assay format.

"The study of epigenetics is rapidly growing and presents opportunities for drug discovery, resulting in an increased need for high quality reagents," said Mark Roskey, vice president and general manager, Reagents, Life Sciences and Technology, PerkinElmer. "We now provide the most comprehensive reagent portfolio for epigenetic drug discovery. Our solutions are highly validated with detailed, ready-to-use protocols, and optimized for simplicity and throughput, marking our commitment to this expanding area of research."

PerkinElmer's epigenetic portfolio provides researchers access to fully validated reagents and assay development services that offer valuable time savings in the race to discover novel drug candidates. These highly specific reagents along with PerkinElmer's knowledge support for the development of epigenetic assays allow researchers to identify and characterize their lead compounds more quickly and efficiently.

Advertisement